81 citations
,
February 2000 in “Anti-cancer drugs” Doxil showed some effectiveness against advanced prostate cancer but caused severe side effects at higher doses.
1 citations
,
October 2020 in “Journal of Cosmetic Dermatology” Using minoxidil and tofacitinib together can effectively treat severe hair loss.
September 2024 in “Skin Appendage Disorders” Tofacitinib helped a woman regrow her hair without relapses after other treatments failed.
1 citations
,
April 2004 in “Cancer” Imatinib mesylate can cause skin lightening, especially in Chinese patients, due to its effect on pigment production.
February 2026 in “Indian Journal of Dermatology” Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.
October 2020 in “Der Hautarzt” Tofacitinib helped regrow hair in a woman with alopecia areata.
October 2018 in “The American journal of gastroenterology” Pembrolizumab can cause serious liver issues, requiring close monitoring and early treatment.
April 2026 in “Clinical Journal of Gastroenterology” Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.
Vismodegib effectively treats advanced basal cell carcinoma but requires careful management of serious side effects.
65 citations
,
March 2004 in “Journal of Clinical Investigation” Inhibiting ornithine decarboxylase may help prevent certain skin cancers.
1 citations
,
June 2023 in “Advances in therapy” Ripretinib is effective and safe for treating advanced GIST in Chinese patients, particularly for non-gastric GISTs.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improved multiple immune-related conditions in one patient.
September 2023 in “International Journal of Applied Pharmaceutics” The formulated gel is a promising treatment for alopecia areata.
1 citations
,
April 2024 in “Anais Brasileiros de Dermatologia”
3 citations
,
August 2024 in “Frontiers in Oncology” Targeted radionuclide therapy shows promise for improving head and neck cancer treatment but needs more research.
3 citations
,
October 2018 in “Journal of Mind and Medical Sciences” Biological therapy boosts the immune system to effectively fight melanoma.
October 2025 in “Frontiers in Medicine” Ixekizumab has known and some unexpected side effects.
4 citations
,
January 2011 in “International Journal of Clinical Medicine” Patients with metastatic breast cancer treated with epirubicin and docetaxel had a good response and maintained their quality of life.
February 2021 in “Research Square (Research Square)” The Li-Pa/Ca and Do/Ca chemotherapy regimens for serous ovarian cancer showed better short-term and long-term results than the Pa/Ca regimen.
388 citations
,
September 2000 in “Cancer” Doxil's toxicity varies with dose and schedule, and pharmacokinetic guidance can optimize dosing.
21 citations
,
November 2018 in “Journal of the European Academy of Dermatology and Venereology” The combination of encorafenib and binimetinib caused few skin issues.
2 citations
,
February 2025 in “Free Radical Biology and Medicine” Blocking S100A8 can reduce chemotherapy-induced hair loss.
1 citations
,
March 2004 in “Journal of the American Academy of Dermatology” ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.
3 citations
,
April 2020 in “PubMed” Combining DEB-BACE with chemotherapy is more effective and has fewer side effects than chemotherapy alone for treating unresectable lung squamous cell carcinoma.
January 2024 in “Journal of Crohn's and colitis” Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.
March 2018 in “International journal of basic and clinical pharmacology” Carboplatin-paclitaxel is preferred for advanced lung cancer due to its balance of affordability and patient well-being.
April 2026 in “bioRxiv (Cold Spring Harbor Laboratory)” A new microneedle patch significantly improves melanoma treatment by using a special material to activate cancer-fighting drugs and disrupt cancer cells.
7 citations
,
November 2021 in “JAAD Case Reports” Mogamulizumab can cause hair loss and skin rashes.
306 citations
,
August 2011 in “Journal of cachexia, sarcopenia and muscle” Enobosarm significantly increased muscle mass and improved physical function in elderly men and postmenopausal women without serious side effects.
27 citations
,
January 2018 in “Drug Delivery” GC10/DOX hydrogel shows promise as an effective thyroid cancer treatment.